1. Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand
   Hitesh Kulhari et al, 2015, Med. Res. Rev. CrossRef
2. Targeted therapies in gastric cancer and future perspectives
   Ozan Yazici, 2016, WJG CrossRef
3. Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
   Yoriko Yamashita-Kashima et al, 2017 CrossRef
4. Biomarkers of gastric cancer: Current topics and future perspective
   Tasuku Matsuoka et al, 2018, WJG CrossRef
5. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates
   Yuqin Yao et al, 2015, Journal of Controlled Release CrossRef
6. HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer
   Hazel Lote et al, 2018, WJGO CrossRef
7. null
   L. V. K. S. Bhaskar et al, 2018 CrossRef
8. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate
   Yoriko Yamashita-Kashima et al, 2019, Cancer Chemother Pharmacol CrossRef
9. null
   Elizabeth Won et al, 2015 CrossRef
10. null
    Jonathan Cools-Lartigue et al, 2015 CrossRef
11. Biomarkers of drugs targeting HER-family signalling in cancer
    Filippo Montemurro et al, 2014, J. Pathol. CrossRef
12. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells
    C. D'Avino et al, 2014, Protein Engineering Design and Selection CrossRef
13. HER2 Directed Therapy for Gastric/Esophageal Cancers
    Elizabeth Won et al, 2014, Curr. Treat. Options in Oncol. CrossRef
14. Investigational therapies targeting the ErbB family in oesophagogastric cancer
    Sing Yu Moorcraft et al, 2014, Expert Opinion on Investigational Drugs CrossRef
15. Nouvelles approches thérapeutiques dans le cancer du sein HER2 positif
    C. Villanueva et al, 2017, Oncologie CrossRef
16. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
    Cornelius Cilliers et al, 2016, AAPS J CrossRef
17. null
    Gail D. Lewis Phillips et al, 2016 CrossRef
18. null
    Beverly A. Teicher, 2017 CrossRef
19. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1)
    Aman P. Singh et al, 2017, AAPS J CrossRef
20. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation
    Aman P. Singh et al, 2020, AAPS J CrossRef
21. Targeted therapies for gastric cancer: failures and hopes from clinical trials
    Maria Apicella et al, 2017, Oncotarget CrossRef
22. null
    Dhananjay Shukla et al, 2020 CrossRef
23. PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
    Edmund I. Graziani et al, 2020, Mol Cancer Ther CrossRef
24. The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery
    Sofia Batalha et al, 2021, Cancers CrossRef
25. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
    Patrícia M. R. Pereira et al, 2022, Nat Commun CrossRef
26. Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
    Yang Zheng et al, 2023, Front. Mol. Biosci. CrossRef
27. Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
    Jia-Lin Hao et al, 2024, Gastric Cancer CrossRef
28. Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)
    Bruna Scheuher et al, 2024, J Pharmacokinet Pharmacodyn CrossRef
29. Advancing gastric cancer treatment: nanotechnology innovations and future prospects
    Tengfei Yang et al, 2024, Cell Biol Toxicol CrossRef